KRAS and cancer: The most prominent findings were their involvement in TNFA via NFKB signaling, an upregulated KRAS signaling, in P53 and apoptosis pathways, along with interactions with immunologically and cancer relevant mechanisms such as E2F-target, IL2-STAT5 signaling, inflammatory response.